biology-news/;menu1239.additem(

Breaking Biology Technology:Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 2 Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 3 Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 4 Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 5 Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 6 Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 7 Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 8 PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision 2 Vivakor Announces Mechanics of Dividend Distribution 2 Vivakor Announces Mechanics of Dividend Distribution 3 Eidogen-Sertanty Licenses TIP to the FDA 2

[0] Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective [0] PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision [0] Vivakor Announces Mechanics of Dividend Distribution [0] Eidogen-Sertanty Licenses TIP to the FDA

Breaking Medicine Technology:Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 2 Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 3 Free Wheelchair Mission Breaks List of Top 60 OC Nonprofits in 2009 2 Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2 Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3 Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4 Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5 Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6 L A Zoo Announces Successful Cancer Treatment of Rhinoceros With Electronic Brachytherapy 6309 1 L A Zoo Announces Successful Cancer Treatment of Rhinoceros With Electronic Brachytherapy 6309 2 L A Zoo Announces Successful Cancer Treatment of Rhinoceros With Electronic Brachytherapy 6309 3 Par Pharmaceutical to Host Analyst Day on December 3rd 6307 1 NeurogesX Receives FDA Approval of Qutenza 28TM 29 28capsaicin 29 8 25 Patch for Treatment of Postherpetic Neuralgia 28PHN 29 6305 1 NeurogesX Receives FDA Approval of Qutenza 28TM 29 28capsaicin 29 8 25 Patch for Treatment of Postherpetic Neuralgia 28PHN 29 6305 2 NeurogesX Receives FDA Approval of Qutenza 28TM 29 28capsaicin 29 8 25 Patch for Treatment of Postherpetic Neuralgia 28PHN 29 6305 3 NeurogesX Receives FDA Approval of Qutenza 28TM 29 28capsaicin 29 8 25 Patch for Treatment of Postherpetic Neuralgia 28PHN 29 6305 4 NeurogesX Receives FDA Approval of Qutenza 28TM 29 28capsaicin 29 8 25 Patch for Treatment of Postherpetic Neuralgia 28PHN 29 6305 5

[0] Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly [0] Free Wheelchair Mission Breaks List of Top 60 OC Nonprofits in 2009 [0] Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia